ABSTRACT β-adrenergic signaling plays an important role in the natural history of dilated cardiomyopathies.
INTRODUCTION
β-adrenergic signaling plays an important antithetical role in the natural history of Dilated Cardiomyopathies (DCMs), exerting both favorable compensatory effects on cardiac function and promoting the development and progression of the DCM phenotype (4, 6, 11, 13) . Activation of β-adrenergic receptors (β 1 -AR and β 2 -AR) during periods of cardiac stress initially results in increases in heart rate and contractility, effectively improving cardiac output, but then ultimately harms the failing heart (5, 8) by mechanisms that include alterations in gene expression (19) . Unfortunately, however, the elucidation of the pathways involved in the harmful components of β-adrenergic signaling has been hindered by a lack of a reliable experimental model.
At the cellular level, myocardial failure is characterized by changes in the expression of genes involved in many critical functions of the cardiac myocyte, including those comprising the contractile apparatus. A subset of these molecular changes has been described as a recapitulation of a "fetal" gene program because many embryonically-expressed genes that are down-regulated postnatally are reactivated, while several "adult" genes are repressed (15) . Of the changes that are observed in failing hearts, increases in expression of the fetal genes skeletal α-actin and atrial natriuretic peptide (ANP), with coordinate decreases in expression of αmyosin heavy chain (αMyHC), the ratio of αMyHC:βMyHC, and sarcoplasmatic reticulum ATPase 2a (SRCA2a), are the most widely recognized.
In the intact heart, chronic β-adrenergic stimulation of the myocardium has been shown to change gene expression patterns in a manner that also mimics the fetal gene program observed in failing hearts (3, 19, 27) . Several β-adrenergic receptor blocking agents have been identified that successfully treat heart failure patients with DCMs by acting to favorably alter the biology of the failing heart (7). It was recently shown that patients with DCMs who respond to β 1 -adrenergic receptor blockade by an improvement in systolic function and a reversal of remodeling also have a reversal of the fetal gene expression (19) . In these responder's hearts, the ratio of αMyHC:βMyHC expression and total SRCA2a are increased, while ANP gene expression is reduced (19) . Given the evidence of the importance of β-adrenergic signaling in heart muscle disease and heart failure, elucidation of the molecular details of how β-adrenergic stimulation leads to fetal gene induction could lead to the identification of additional therapeutic targets.
Neonatal rat ventricular myocytes (NRVMs) have been used successfully by many investigators as a cell culture model for investigating several signaling pathways involved in heart disease. In the case of β-adrenergic signaling, however, NRVMs have been problematic. That is, treatment of NRVMs with isoproterenol, a nonselective β-AR agonist, induces myocyte hypertrophy similar to that observed in cardiac disease. However, this hypertrophic response does not consistently induce a fetal gene program (18, 31). As a result, little progress has been made in dissecting the effects of β-adrenergic activation. Moreover, the question of whether β-adrenergic stimulation can directly elicit a comprehensive fetal gene response has been raised.
In the work presented here, we demonstrate that the stimulation of NRVMs with 10nM to 1µΜ isoproterenol can consistently induce an up-regulation of ANP, brain natriuretic peptide (BNP) and skeletal α-actin expression, and a down-regulation of αMyHC and Serca 2a,. This change is easily monitored by measuring the relative activities of the human and rat cardiac MyHC gene promoters, making this system a valuable model for experimentally examining the molecular pathways involved in β-adrenergic activation. As a proof of principle, we go on to show that the isoproterenol-induced fetal response is specifically mediated by the β 1 -AR, and not the β 2 -AR. Surprisingly, the β 1 -AR fetal gene response is independent of cAMP, since treatment of the cells with cAMP analogs had no effect on the activity of MyHC promoters or endogenous fetal/adult gene expression, and pre-treatment of myocytes with protein kinase A (PKA) inhibitors did not affect isoproterenol-mediated responses. Furthermore, we provide evidence that Ca 2+ /calmodulin kinase (CaMK) appears to play an important role in the isoproterenol-mediated fetal gene response since inhibition of CaMK resulted in an inhibition of isoproterenol-mediated effects. Finally, we show that isoproterenol-mediated induction of the FGP is dependent on activation of Ca 2+ channels since inhibition of the L-Type Ca 2+ channel (LTCC) channels results in inhibition of the isoproterenol effects on the FGP. Our results suggest that changes in gene expression mediated by β 1 -adrenergic stimulation occur through a cAMP independent pathway, and are likely to occur through a Ca 2+ related mechanism. 
MATERIAL AND METHODS

Materials
Plasmid construction and preparation:
The human αMyHC promoter construct, rat αMyHC promoter construct βMyHC promoter construct have been described previously (21, 32 Transfection experiments were done in tripliclates in six or more different experiments (n > 18). In cotransfection experiments, the total DNA amount was kept constant by the addition of an empty vector.
RNase Protection Assay:
Total cellular RNA was extracted with TRIZol (Invitrogen) for use in RNase protection assays (RPAs). RPAs were performed essentially as described (24) (12). Briefly, 5 µg of RNA was hybridized against 32 P-labeled RNA probes specific to skeletal α-actin, SRCA2A, α-MyHC, β-MyHC, ANF, BNP and GAPDH. RNase protection experiments (RPAs) were performed using the RPAII kit (Ambion). RPA experiments were performed from mRNA extracted from a minimum of three different experiments.
Incorporation of 3 H-leucine:
General cell growth was measured by the incorporation of 3 H-leucine as described previously (20). Immediately following treatment of cells with isoproterenol and/or adrenergic receptor blockers, 1µCi of 3 H-leucine was added to each well (12-well plates) of NRVMs.
After 48 hours, plates were washed two times with ice-cold PBS. The cells were precipitated on ice with 5%TCA. Proteins were then solubilized by the addition of 0.1% SDS and incubation at 37 o C on a rocker for 4 hours. 3 H-leucine incorporation was measured by scintillation counter.
Immunofluorescence: Immunofluorescence was done according to Harrison et al(9) . 
RESULTS
Isoproterenol induces fetal gene expression of pathological markers
Although NRVMs have been used successfully to study the molecular and cellular effects of many pathology-asociated biologic substances, their use for the examination of β-adrenergic stimulation has yielded conflicting results, making it difficult to study β-AR mediated signaling pathways in a cell culture model. It is possible that the lack of β-AR response in NRVMs is related to cell density and/or hypertrophic conditions in the media. With this in mind, special care was taken during the isolation and culturing of NRVMs to prevent cell damage, reduce fibroblast contamination, minimize contactmediated stimulation by plating the cells at low density, and remove all traces of serum after plating.
As shown in Figure 1 we are able to consistently prepare cells that have measurable pathological responses to β-AR stimulation. 100nM isoproterenol treatment resulted in a decrease in αMyHC and SRCA2a gene expression, and although βMyHC gene expression was not increased, there was a decrease in the ratio of αMyHC:βMyHC mRNA, which is consistent with a pathological response.
Consistent with a pathologic response, skeletal α-actin, BNP and ANP mRNA expression were upregulated ( figure 1A) . Furthermore, isoproterenol treatment causes significant increase in protein synthesis as measured by an increase in the incorporation of 3 H-leucine compared to untreated control ( Figure 1B ). Measurement of labeled amino acid incorporation has been previously described and validated as a marker of cardiac myocyte hypertrophy (16, 17, 29, 30) . These data clearly indicate that a fetal gene response is elicited in these cells and confirm our ability to use NRVMs as a model for studying β-AR signaling.
Promoter studies demonstrate fetal response to isoproterenol treatment
In order to further demonstrate that isoproterenol elicits fetal changes in gene expression in NRVMs and provide a useful technique for measuring these changes, we transfected NRVMs with heterologous promoter constructs in which either the human or rat αMyHC promoters and the human ANP or rat βMyHC promoters were driving the expression of luciferase. As shown in Figure 2 A-D, treatment of NRVMs with 10 nM to 1 µM of isoproterenol results in a fetal response in each of these reporter constructs. More specifically, the human and rat αMyHC-luc promoter activities are repressed by isoproterenol treatment while the activities of the human ANP-luc and rat βMyHC-luc reporter constructs are increased. Since the β-AR response elicits repression of αMyHC promoter at a 10nM to 1 µM isoproterenol range, all subsequent experiments were performed with 100 nM isoproterenol.
The fetal gene response is mediated through β 1 -AR and not through β 2 -AR In order to confirm that the fetal gene response observed in the promoter-reporter experiments is specifically mediated through β-ARs, the pharmacological β-AR antagonist propranolol was used in combination with isoproterenol treatment of NRVMs. As shown in Figure 3 , the addition of propranolol prevented the isoproterenol-mediated repression of both the human and rat αMyHC-luc reporters as well as the activation of the βMyHC-luc reporter.
These data led us to ask which β-adrenergic receptor, β 1 -AR or β 2 -AR, is mediating the fetal gene response. In order to answer this question, each receptor was blocked individually by the addition of the receptor specific blockers CGP 20712A and ICI 118551, which selectively inhibit the β 1 -AR and β 2 -AR, respectively. As shown in Figure 3 , CGP20712A, but not ICI 118551, blocks the isoproterenolmediated changes in promoter activities of our reporter constructs, indicating that the fetal gene response to isoproterenol treatment is mediated through β 1 -ARs and not through β 2 -ARs.
Endogenous changes are specifically mediated by β 1 -AR
In order to confirm that our reporter studies were accurately reflecting the regulation of endogenous responses to isoproterenol through the β 1 -AR, mRNA levels of the fetal gene program was measured. As shown in Figure 4A , repression of SRCA2a and αMyHC, and activation of BNP, ANP and skeletal α-actin in response to isoproterenol are all blocked by CGP20712A but not by ICI 118551, consistent with the promoter-reporter system. Increase in protein synthesis, however, was blocked by the β 1 -AR blocker, CGP20712A and by the β 2 -AR blocker ICI 118551 ( Figure 4B ). Taken together, these data demonstrate that isoproterenol induces a pathological response in NRVMs that is specifically mediated by activation of the β 1 -adrenergic receptor.
Isoproterenol-mediated changes in the fetal gene program do not occur through α-AR. To rule out the possibility that the changes in promoter activity were not mediated by α 1 -ARs, cells were treated with 1 µM of the specific α 1 -AR antagonist prazosin prior to treatment with isoproterenol. α 1 -AR blockade did not affect αMyHC, βMyHC or ANP promoter activity at isoproterenol concentrations of 100 nM or 1 µM, providing further evidence that lower concentrations of isoproterenol induces the fetal gene program through a β-adrenergic mediated pathway ( Figure 5 ). However, at higher concentrations, prazosin reduced the isoproterenol effect, suggesting that at concentrations higher than 1µM, isoproterenol activation is leaky and stimulates the αAR pathway.
Inhibition of isoproterenol-activation of the FGP is independent of PKA. In cardiac myocytes, many Although PKA inhibition reduced the degree of inhibition of ANP, BNP and skeletal α-actin, these genes were still up-regulated in response to isoproterenol (Figure 8 ). To confirm the results with the pharmacological treatment, cells were transfected with the human αMyHC-luc vector promoter and a construct that expresses a constitutively active form of PKA (caPKA). caPKA did not change the activity of the αMyHC promoter ( Figure 6C ). As a positive control for PKA mediated effects, a synthetic promoter construct containing 3 copies of the CRE binding site was co-transfected with caPKA in NRVMs; this construct was up-regulated by the caPKA (data not shown). 
Isoproteremol mediated changes in promoter activity
DISCUSSION
In this study we demonstrate that isoproterenol induces a hypertrophic response in NRVMs as measured by an induction of the fetal gene program as well as an increase in cellular incorporation of radio-labeled leucine. The changes in gene expression invoked by isoproterenol were similar to those observed in the intact hearts of adult animals and human subjects exhibiting pathological hypertrophy and myocardial failure (3, 19) . This fetal gene expression response to isoproterenol is β-AR specific and is not mediated through α 1 -ARs. The fetal gene response is mediated through a β 1 -AR receptor pathway that is cAMP and PKA independent, but dependent on CaMKII and LTCC.
Previous studies in NRVMs were unable to detect a change in endogenous MyHC levels with β-adrenergic stimulation, suggesting that in this system β-adrenergic pathways were not involved in the fetal gene response (31) , despite the fact that β-adrenergic stimulation has been shown to increase ANP gene expression (2, 23). This lack of a comprehensive β-adrenergic fetal gene induction in NRVMs was in contrast to results in adult rat intact myocardium as well as clinical data in the human heart (3, 19, 27) . However, our data indicate that NRVM treatment with isoproterenol demonstrated a fetal gene response as assessed by the activities of αMyHC, βMyHC and ANP reporter constructs, as well as an increase in protein synthesis based on increased levels of 3 H-leucine incorporation. As argued previously (18), the hypertrophy observed in NRVMs upon treatment with isoproterenol could be dependent on increased contractility and thus might not be associated with the changes in gene expression that ordinarily accompany pathological hypertrophy. However, we demonstrated that β-adrenergic stimulation alters the activities of the human and rat cardiac MyHC promoters and human ANP promoter in directions consistent with the "fetal" gene response that is considered to be the molecular marker of pathological hypertrophy (33). Several important conclusions can be drawn from these data. First, the use of transiently transfected luciferase reporters can serve as a convenient assay for measuring the pathological effects of isoproterenol treatment on NRVMs. The results of the luciferase assays closely mimicked the endogenous mRNA data shown in Figure 1 , providing a useful tool for observing the fetal gene response in these cells. Second, the ability of isoproterenol to elicit a pathological response of the αMyHC promoter falls within a defined range of isoproterenol concentrations. As can be seen in Figure 2A and 2C, there is no significant response of the αMyHC promoter when the isoproterenol concentration is lower than 10nM or higher than 1µΜ. At lower concentrations, there is likely insufficient activation of the β-ARs to elicit a fetal response. At higher concentrations, however, α-AR pathway is activated that eclipse β-adrenergic signaling, preventing the repression of the αMyHC promoter.
Moreover, isoproterenol induced a fetal pattern of endogenous gene expression in NRVMs with repression of SRCA2a mRNA expression and activation of skeletal α-actin, BNP and ANP mRNA expression. Importantly, the αMyHC:βMyHC ratio is down-regulated, and the alteration in this balance is likely responsible for the changes in contractile activity as seen in experiments with single cells (10) .
Changes in αMyHC:βMyHC ratios without activation of βMyHC gene expression have also been observed in failing human hearts (19) . Taken together, these data demonstrate that β-adrenergic pathway is able to induce "pathological" hypertrophy and a fetal gene program response in NRVMs. Recent work in NRVMs has shown that CaMKII is involved in β-AR mediated response in both cases independent of cAMP and PKA (35, 37, 40 Each mRNA was normalized to GAPDH.
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